BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 21620777)

  • 1. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.
    Mulholland DJ; Tran LM; Li Y; Cai H; Morim A; Wang S; Plaisier S; Garraway IP; Huang J; Graeber TG; Wu H
    Cancer Cell; 2011 Jun; 19(6):792-804. PubMed ID: 21620777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
    Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ
    Carcinogenesis; 2012 Feb; 33(2):404-12. PubMed ID: 22159221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.
    Tien JC; Liu Z; Liao L; Wang F; Xu Y; Wu YL; Zhou N; Ittmann M; Xu J
    Cancer Res; 2013 Jul; 73(13):3997-4008. PubMed ID: 23650284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
    Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
    Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex.
    Shang Z; Yu J; Sun L; Tian J; Zhu S; Zhang B; Dong Q; Jiang N; Flores-Morales A; Chang C; Niu Y
    Nucleic Acids Res; 2019 May; 47(8):4211-4225. PubMed ID: 30773595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy.
    Ding L; Chen S; Liu P; Pan Y; Zhong J; Regan KM; Wang L; Yu C; Rizzardi A; Cheng L; Zhang J; Schmechel SC; Cheville JC; Van Deursen J; Tindall DJ; Huang H
    Cancer Res; 2014 Apr; 74(7):2050-61. PubMed ID: 24491799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma.
    Molina JR; Agarwal NK; Morales FC; Hayashi Y; Aldape KD; Cote G; Georgescu MM
    Oncogene; 2012 Mar; 31(10):1264-74. PubMed ID: 21804599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
    Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
    Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN and PHLPP crosstalk in cancer cells and in TGFβ-activated stem cells.
    Ghalali A; Ye ZW; Högberg J; Stenius U
    Biomed Pharmacother; 2020 Jul; 127():110112. PubMed ID: 32294598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
    Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
    J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.
    Shiota M; Song Y; Yokomizo A; Tada Y; Kuroiwa K; Eto M; Oda Y; Inokuchi J; Uchiumi T; Fujimoto N; Seki N; Naito S
    Endocr Relat Cancer; 2010 Jun; 17(2):455-67. PubMed ID: 20308360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
    Sharma M; Chuang WW; Sun Z
    J Biol Chem; 2002 Aug; 277(34):30935-41. PubMed ID: 12063252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
    Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D
    Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
    Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
    Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
    Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
    Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
    Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
    Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
    Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.